 Liyen Loh
Concepts (198)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mucosal-Associated Invariant T Cells | 10 | 2022 | 16 | 2.430 |
Why?
| | CD8-Positive T-Lymphocytes | 19 | 2023 | 689 | 2.370 |
Why?
| | Simian Acquired Immunodeficiency Syndrome | 13 | 2014 | 68 | 1.910 |
Why?
| | Simian Immunodeficiency Virus | 12 | 2014 | 70 | 1.860 |
Why?
| | Influenza A virus | 10 | 2022 | 90 | 1.560 |
Why?
| | Influenza, Human | 14 | 2022 | 546 | 1.560 |
Why?
| | Influenza A Virus, H7N9 Subtype | 5 | 2018 | 5 | 0.970 |
Why?
| | Leukocytes, Mononuclear | 7 | 2022 | 493 | 0.900 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 4 | 2023 | 309 | 0.830 |
Why?
| | Coculture Techniques | 2 | 2020 | 201 | 0.790 |
Why?
| | Epitopes, T-Lymphocyte | 7 | 2022 | 170 | 0.750 |
Why?
| | Gene Products, gag | 6 | 2012 | 36 | 0.740 |
Why?
| | Alveolar Epithelial Cells | 1 | 2020 | 93 | 0.640 |
Why?
| | Killer Cells, Natural | 5 | 2023 | 382 | 0.530 |
Why?
| | Immunity, Mucosal | 1 | 2016 | 84 | 0.510 |
Why?
| | Immunologic Memory | 6 | 2020 | 313 | 0.510 |
Why?
| | Macaca nemestrina | 13 | 2014 | 28 | 0.500 |
Why?
| | Interleukin-18 | 1 | 2016 | 219 | 0.490 |
Why?
| | T-Lymphocytes, Cytotoxic | 3 | 2010 | 155 | 0.390 |
Why?
| | Pneumonia, Viral | 1 | 2016 | 340 | 0.380 |
Why?
| | Immunophenotyping | 4 | 2020 | 275 | 0.360 |
Why?
| | T-Lymphocyte Subsets | 4 | 2024 | 384 | 0.360 |
Why?
| | Thymus Gland | 3 | 2023 | 296 | 0.340 |
Why?
| | Immunity, Cellular | 3 | 2018 | 248 | 0.330 |
Why?
| | CD4-Positive T-Lymphocytes | 7 | 2021 | 965 | 0.320 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2021 | 127 | 0.320 |
Why?
| | Genes, gag | 1 | 2008 | 3 | 0.320 |
Why?
| | Viruses | 2 | 2020 | 94 | 0.320 |
Why?
| | Granzymes | 2 | 2020 | 40 | 0.300 |
Why?
| | Lymphocyte Activation | 5 | 2020 | 1044 | 0.300 |
Why?
| | Interferon-gamma | 4 | 2020 | 722 | 0.290 |
Why?
| | Mutation | 6 | 2014 | 3350 | 0.280 |
Why?
| | Immunotherapy | 5 | 2024 | 475 | 0.280 |
Why?
| | Cell Communication | 2 | 2020 | 279 | 0.270 |
Why?
| | Cytokines | 4 | 2021 | 1843 | 0.260 |
Why?
| | Monocytes | 2 | 2020 | 503 | 0.250 |
Why?
| | Receptors, Antigen, T-Cell | 4 | 2024 | 618 | 0.240 |
Why?
| | Vaccination | 5 | 2021 | 1205 | 0.240 |
Why?
| | Aging | 3 | 2020 | 1620 | 0.240 |
Why?
| | B-Lymphocytes | 2 | 2021 | 769 | 0.240 |
Why?
| | Blood | 2 | 2019 | 96 | 0.230 |
Why?
| | Cell Differentiation | 3 | 2020 | 1699 | 0.220 |
Why?
| | Immunity, Innate | 2 | 2020 | 723 | 0.210 |
Why?
| | Viremia | 3 | 2008 | 123 | 0.210 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 137 | 0.200 |
Why?
| | Influenza Vaccines | 3 | 2022 | 498 | 0.190 |
Why?
| | Histocompatibility Antigens Class I | 4 | 2022 | 174 | 0.190 |
Why?
| | HLA-A24 Antigen | 1 | 2021 | 5 | 0.190 |
Why?
| | Animals | 21 | 2021 | 31762 | 0.190 |
Why?
| | DNA, Viral | 2 | 2014 | 350 | 0.190 |
Why?
| | Forkhead Box Protein O1 | 1 | 2021 | 15 | 0.190 |
Why?
| | Cellular Senescence | 2 | 2021 | 152 | 0.180 |
Why?
| | HLA-B27 Antigen | 1 | 2020 | 11 | 0.180 |
Why?
| | Immunodominant Epitopes | 1 | 2020 | 26 | 0.180 |
Why?
| | Cells, Cultured | 4 | 2021 | 3890 | 0.180 |
Why?
| | Viral Load | 3 | 2019 | 405 | 0.180 |
Why?
| | Lysosomal-Associated Membrane Protein 1 | 1 | 2020 | 5 | 0.170 |
Why?
| | Natural Killer T-Cells | 1 | 2020 | 63 | 0.170 |
Why?
| | Virus Replication | 3 | 2012 | 395 | 0.170 |
Why?
| | Humans | 30 | 2024 | 114757 | 0.170 |
Why?
| | Antibody Formation | 1 | 2021 | 267 | 0.170 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 79 | 0.170 |
Why?
| | Proviruses | 1 | 2019 | 9 | 0.160 |
Why?
| | HTLV-I Infections | 1 | 2019 | 21 | 0.160 |
Why?
| | HLA-B37 Antigen | 1 | 2018 | 1 | 0.160 |
Why?
| | HLA-A1 Antigen | 1 | 2018 | 3 | 0.160 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 2019 | 23 | 0.160 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 188 | 0.160 |
Why?
| | Extracellular Vesicles | 1 | 2020 | 83 | 0.160 |
Why?
| | Antibodies, Viral | 4 | 2018 | 521 | 0.160 |
Why?
| | SAIDS Vaccines | 2 | 2009 | 3 | 0.160 |
Why?
| | Australia | 4 | 2022 | 207 | 0.160 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2019 | 45 | 0.160 |
Why?
| | Orthomyxoviridae Infections | 1 | 2018 | 54 | 0.150 |
Why?
| | Clonal Selection, Antigen-Mediated | 1 | 2018 | 3 | 0.150 |
Why?
| | T-Lymphocytes | 4 | 2020 | 1745 | 0.150 |
Why?
| | HIV Infections | 4 | 2014 | 2469 | 0.150 |
Why?
| | Respiratory System | 1 | 2019 | 137 | 0.150 |
Why?
| | Virus Diseases | 1 | 2020 | 195 | 0.150 |
Why?
| | Cross Reactions | 2 | 2014 | 117 | 0.140 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 295 | 0.140 |
Why?
| | NK Cell Lectin-Like Receptor Subfamily B | 1 | 2016 | 10 | 0.140 |
Why?
| | Multiple Myeloma | 1 | 2018 | 93 | 0.140 |
Why?
| | Survival Analysis | 2 | 2018 | 1218 | 0.140 |
Why?
| | RNA, Viral | 2 | 2012 | 566 | 0.140 |
Why?
| | Hypersensitivity | 1 | 2020 | 254 | 0.140 |
Why?
| | A549 Cells | 1 | 2016 | 51 | 0.140 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 928 | 0.130 |
Why?
| | Escherichia coli | 1 | 2020 | 722 | 0.130 |
Why?
| | Minor Histocompatibility Antigens | 3 | 2022 | 41 | 0.130 |
Why?
| | AIDS Vaccines | 3 | 2010 | 41 | 0.130 |
Why?
| | Influenza A Virus, H1N1 Subtype | 2 | 2014 | 139 | 0.120 |
Why?
| | Adult | 10 | 2021 | 30548 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2020 | 1134 | 0.120 |
Why?
| | HIV Antibodies | 1 | 2014 | 49 | 0.120 |
Why?
| | Antibody-Dependent Cell Cytotoxicity | 1 | 2014 | 19 | 0.120 |
Why?
| | Aged | 7 | 2021 | 19094 | 0.120 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2014 | 122 | 0.110 |
Why?
| | Cell Line, Tumor | 1 | 2020 | 2725 | 0.110 |
Why?
| | Middle Aged | 7 | 2021 | 26757 | 0.110 |
Why?
| | Transcriptome | 1 | 2018 | 727 | 0.100 |
Why?
| | Influenza B virus | 2 | 2022 | 34 | 0.100 |
Why?
| | Genetic Engineering | 2 | 2009 | 80 | 0.100 |
Why?
| | Gene Expression | 1 | 2016 | 1420 | 0.090 |
Why?
| | HIV-1 | 2 | 2014 | 768 | 0.090 |
Why?
| | Mice, Inbred C57BL | 4 | 2021 | 4710 | 0.090 |
Why?
| | Neoplasms | 1 | 2024 | 2105 | 0.090 |
Why?
| | Male | 10 | 2021 | 55579 | 0.090 |
Why?
| | Young Adult | 6 | 2021 | 10463 | 0.080 |
Why?
| | HIV | 2 | 2009 | 208 | 0.080 |
Why?
| | Disease Models, Animal | 4 | 2020 | 3542 | 0.080 |
Why?
| | Gene Expression Regulation | 3 | 2018 | 2321 | 0.080 |
Why?
| | Adoptive Transfer | 2 | 2020 | 198 | 0.080 |
Why?
| | HLA-A Antigens | 2 | 2022 | 50 | 0.080 |
Why?
| | Female | 9 | 2021 | 59507 | 0.080 |
Why?
| | Replicon | 1 | 2008 | 14 | 0.080 |
Why?
| | West Nile virus | 1 | 2008 | 38 | 0.070 |
Why?
| | Vaccines, Synthetic | 1 | 2008 | 124 | 0.070 |
Why?
| | Models, Biological | 1 | 2014 | 1630 | 0.070 |
Why?
| | Oligopeptides | 1 | 2008 | 234 | 0.070 |
Why?
| | Peptides | 3 | 2022 | 849 | 0.070 |
Why?
| | Molecular Sequence Data | 2 | 2008 | 2791 | 0.070 |
Why?
| | Hemagglutinin Glycoproteins, Influenza Virus | 2 | 2018 | 20 | 0.070 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 994 | 0.060 |
Why?
| | Cohort Studies | 3 | 2021 | 4901 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 912 | 0.060 |
Why?
| | Base Sequence | 1 | 2008 | 2118 | 0.060 |
Why?
| | Signal Transduction | 1 | 2016 | 4522 | 0.060 |
Why?
| | Mice | 4 | 2021 | 14916 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2021 | 6350 | 0.050 |
Why?
| | Immunoglobulins | 1 | 2023 | 143 | 0.050 |
Why?
| | Receptors, KIR | 1 | 2023 | 92 | 0.050 |
Why?
| | Mice, Knockout | 2 | 2020 | 2582 | 0.050 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1521 | 0.050 |
Why?
| | Amino Acid Sequence | 2 | 2021 | 1988 | 0.050 |
Why?
| | Cell Proliferation | 2 | 2020 | 2196 | 0.050 |
Why?
| | Chronic Disease | 1 | 2008 | 1590 | 0.050 |
Why?
| | Ligands | 1 | 2023 | 565 | 0.050 |
Why?
| | Mucous Membrane | 1 | 2022 | 108 | 0.050 |
Why?
| | Time Factors | 2 | 2010 | 6124 | 0.050 |
Why?
| | Phenotype | 2 | 2019 | 2812 | 0.050 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 433 | 0.050 |
Why?
| | Hospitalization | 2 | 2021 | 1752 | 0.050 |
Why?
| | Thymocytes | 1 | 2020 | 28 | 0.050 |
Why?
| | Dogs | 1 | 2021 | 334 | 0.040 |
Why?
| | Viral Plaque Assay | 1 | 2020 | 24 | 0.040 |
Why?
| | Haloperidol | 1 | 2020 | 35 | 0.040 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2020 | 135 | 0.040 |
Why?
| | Gene Frequency | 1 | 2021 | 481 | 0.040 |
Why?
| | Exudates and Transudates | 1 | 2019 | 12 | 0.040 |
Why?
| | Antigen Presentation | 1 | 2020 | 189 | 0.040 |
Why?
| | Toll-Like Receptors | 1 | 2020 | 166 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 388 | 0.040 |
Why?
| | Alleles | 1 | 2021 | 791 | 0.040 |
Why?
| | Antibody-Producing Cells | 1 | 2018 | 29 | 0.040 |
Why?
| | ADP-ribosyl Cyclase 1 | 1 | 2018 | 35 | 0.040 |
Why?
| | Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2018 | 27 | 0.040 |
Why?
| | Thalidomide | 1 | 2018 | 28 | 0.040 |
Why?
| | Vaccines, Inactivated | 1 | 2018 | 68 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2018 | 78 | 0.040 |
Why?
| | Phylogeny | 1 | 2021 | 794 | 0.040 |
Why?
| | HLA-DR Antigens | 1 | 2018 | 220 | 0.030 |
Why?
| | Lymphoid Progenitor Cells | 1 | 2016 | 11 | 0.030 |
Why?
| | Antigens, CD1d | 1 | 2016 | 63 | 0.030 |
Why?
| | Allergens | 1 | 2020 | 413 | 0.030 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 195 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 1951 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1086 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2018 | 429 | 0.030 |
Why?
| | Antigens, CD | 1 | 2018 | 443 | 0.030 |
Why?
| | Receptors, KIR2DL1 | 1 | 2015 | 18 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2018 | 385 | 0.030 |
Why?
| | Mitochondria | 1 | 2020 | 751 | 0.030 |
Why?
| | Hemagglutination Tests | 1 | 2014 | 7 | 0.030 |
Why?
| | Antiviral Agents | 1 | 2020 | 646 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2020 | 1314 | 0.030 |
Why?
| | Likelihood Functions | 1 | 2014 | 126 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 743 | 0.030 |
Why?
| | Critical Illness | 1 | 2018 | 643 | 0.030 |
Why?
| | HLA Antigens | 1 | 2014 | 224 | 0.030 |
Why?
| | Crystallography, X-Ray | 1 | 2014 | 405 | 0.030 |
Why?
| | Age Factors | 1 | 2017 | 2890 | 0.020 |
Why?
| | MicroRNAs | 1 | 2016 | 601 | 0.020 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2009 | 40 | 0.020 |
Why?
| | Receptors, OX40 | 1 | 2008 | 15 | 0.020 |
Why?
| | Fusion Proteins, gag-pol | 1 | 2008 | 2 | 0.020 |
Why?
| | Viral Vaccines | 1 | 2008 | 88 | 0.020 |
Why?
| | Blood Component Transfusion | 1 | 2008 | 75 | 0.020 |
Why?
| | Random Allocation | 1 | 2008 | 335 | 0.020 |
Why?
| | Models, Animal | 1 | 2009 | 345 | 0.020 |
Why?
| | Longevity | 1 | 2008 | 137 | 0.020 |
Why?
| | Cross-Over Studies | 1 | 2008 | 440 | 0.020 |
Why?
| | Biomarkers | 1 | 2016 | 3416 | 0.020 |
Why?
| | Lung | 1 | 2018 | 3546 | 0.020 |
Why?
| | Sequence Analysis, DNA | 1 | 2008 | 728 | 0.020 |
Why?
| | Cell Line | 1 | 2009 | 2639 | 0.010 |
Why?
| | Adolescent | 1 | 2019 | 17808 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2008 | 9089 | 0.010 |
Why?
|
|
Loh's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|